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Neurotransmitters are also involved in functions other than conventional signal transfer between nerve cells, such as
development, plasticity, neurodegeneration, and neuroprotection. For example, there is a considerable amount of data
indicating developmental roles for the glutamatergic, cholinergic, dopaminergic, GABA-ergic, and ATP/adenosine systems. In
this review, we discuss the existing literature on these “new” functions of neurotransmitters in relation to some unconventional
neurotransmitters, such as the endocannabinoids and nitric oxide. Data indicating both transcriptional and post-transcriptional
modulation of endocannabinoid and nitrinergic systems after neural lesions are discussed in relation to the non-conventional
roles of these neurotransmitters. Knowledge of the roles of neurotransmitters in brain functions other than information transfer
is critical for a more complete understanding of the functional organization of the brain and to provide more opportunities for the
development of therapeutical tools aimed at minimizing neuronal death.
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The endocannabinoid system
Endocannabinoids are defined as endogenous ligands
of the cannabinoid receptors CB1 and CB2 (1). The basal
levels of endocannabinoids are similar in different areas of
the brain, including the brainstem, striatum, hippocampus,
neocortex, diencephalon, and cerebellum. However, pro-
vocative data indicate that there is no direct correlation
between the concentration of the endocannabinoids and the
expression of the CB1 receptor, which suggests that en-
docannabinoids could also be involved in other neurotrans-
mitter systems. Actually, it is also known that these com-
pounds can directly modulate several other receptors, such
as the serotonergic 5-HT2 and 5-HT3 receptors, the glutama-
tergic N-methyl-D-aspartate (NMDA) receptor, and the tran-
sient receptor potential vanilloid type 1 (TRPV1) (2).
The first endocannabinoid to be isolated was N-arachi-
donoylethanolamine, or anandamide, an amide of arachi-
donic acid with ethanolamine. In 1995, 2-arachidonoyl-
glycerol (2-AG) was discovered, an ester of arachidonic
acid with glycerol, which is the most abundant cannabinoid
ligand in the central nervous system. Since then, several
other lipids, all derived from arachidonic acid, have been
shown to modulate the cannabinoid receptors, such as 2-
arachidonoylglycerol ether (noladin ether), O-arachidono-
ylethanolamine (virodhamina), and N-arachidonoyldopa-
mine (3).
Both anandamide and 2-AG are synthesized on de-
mand under neuronal stimulation. Anandamide is pro-
duced by the enzymes N-acyl-phosphatidylethanolamine-
hydrolyzing-phospholipase D and is degraded by fatty acid
amide hydrolase. 2-AG is synthesized by diacylglycerol
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lipase and thus degraded by the monoacylglycerol lipases.
As hydrophobic compounds, they can reach the extracel-
lular fluid, including synaptic terminals, where they can be
taken up by neurons through the anandamide membrane
transporter (AMT) (1). It is interesting that 2-AG has been
found frequently in brain preparations at much higher
concentrations than anandamide. 2-AG seems to occur
both in the final steps of the biosynthetic pathway of certain
lipids, as well as in the initial steps of the production of
other lipids, and thus may participate in cell metabolism
rather than solely as a neuromodulator molecule (3,4).
The regulation of the synthesis of these compounds
has not been completely elucidated. As an example, the
stimulation of NMDA receptors in neuronal cultures from
rat cortex yielded a 3-fold rise in 2-AG production, but no
change was observed in anandamide levels. However,
simultaneous activation of the NMDA and α-7 acetylcho-
line receptors increased the anandamide levels 5-fold,
whereas nicotinic stimulation alone did not cause any
changes in the endocannabinoid levels (5). In addition,
recent findings have shown that endocannabinoid produc-
tion is linked to the rise of intracellular calcium elicited by
protein Gq/11-coupled receptor activation (6). Thus, it is
clear that the molecular mechanisms that underlie the
synthesis of anadamide and 2-AG are distinct and are
probably dependent upon the other neuromodulators that
share the same synaptic terminal.
Cannabinoid receptors
Cannabinoid receptors are coupled to Gi/0 protein that
is sensitive to the psychoactive compound delta-9-tetrahy-
drocannabinol from Cannabis sativa (7). The CB1 receptor
was cloned in the early 1990’s, and since it is found mainly
in neurons, it is known as the neuronal cannabinoid recep-
tor (8). The CB2 receptor was first detected in hematopoi-
etic cells and in the spleen (9) and has been recently
shown to be expressed in neuronal and glial cells in the
central nervous system (10).
Activation of the CB1 receptor has been extensively
implicated in the control of synapse function. Binding of
endogenous ligands to CB1 receptors leads to inhibition of
adenylate cyclase, thus reducing AMPc levels. This has
been implicated in inhibition of pre-synaptic calcium cur-
rents and in the activation of potassium rectifying chan-
nels, therefore inhibiting the release of several neuro-
modulators such as glutamate, dopamine, acetylcholine,
and norepinephrine (1,7).
Several other intracellular pathways such as mitogen-
activated protein-kinase and STAT3 have been shown to
be associated with neuronal maturation, axon outgrowth
and cellular division. Moreover, the CB1 receptor has also
been implicated in the activation of JNK, WAVE and PAK,
which have been implicated in the enhancement of actin
production and polymerization. In turn, this can lead to
neuronal growth (11).
The endocannabinoid system has also been impli-
cated in neuroprotection in neuronal damage models both
in vivo and in vitro (12). These studies have shown in-
creased levels of endocannabinoids and upregulation of
CB1 receptors in rats and mice, which could represent a
protective response. In addition, a receptor reduction is
observed in some neurodegenerative diseases, such as
Huntington’s disease (13).
We reported that unilateral retinal lesions produced an
increase in the immunoreactivity for CB1 in the neuropil of
superficial layers of the deafferented avian optic tectum
and an increased CB1 expression as determined by immu-
noblotting. Unlike what was observed for protein levels,
unilateral retinal ablation did not produce any detectable
changes of CB1 mRNA levels (14). We also observed that
retinal lesions do not seem to generate cell death by
apoptosis in the optic tectum, as evaluated by the TUNEL
method (in situ DNA fragmentation staining). The CB1
increase was accompanied by a microtubule-associated
protein-2 increase.
This study suggests that, as observed for the nitrinergic
system, CB1 expression in visual structures of the chick
brain is negatively regulated by the retinal innervation. Since
we did not observe cell death in the tectum in this lesion
model, the up-regulation of CB1 could indicate the participa-
tion of the cannabinoid system in plasticity processes. Alter-
natively, the up-regulation of CB1 could have some neuro-
protective role as shown in other studies, which have dem-
onstrated increased levels of endocannabinoids and up-
regulation of CB1 receptors in brain injury models in rats and
mice (15,16). In addition, our results suggest a postsynaptic
location of these receptors in tectal layers of the chick brain,
despite the fact that several studies have indicated mainly a
presynaptic localization for CB1 receptors as modulators of
neurotransmission (3). The CB1 receptors in the tectum
could, however, be located on axon terminals of tectal
afferents other than those of retinal origin. This issue clearly
deserves further investigation.
Vanilloid receptor 1
The vanilloid receptors belong to the transient receptor
potential (TRP) channel, a large family of cation channels
mostly permeable to calcium and magnesium. Based on
protein homology, the TRP family can be subdivided into
seven subfamilies: the vanilloid family (TRPV), the canoni-
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cal family, the melastatin family, the polycystin family, the
mucolipin family, the ankyrin family, and the NOMPC fam-
ily (17).
TRPV is composed of six members (TRPV1-6). TRPV1
was the first channel to be identified in the vanilloid subfamily
(18). Given its sensitivity to capsaicin, the pungent com-
pound extracted from the hot chili pepper, the TRPV1 recep-
tor was known as the capsaicin receptor prior to its cloning
and sequencing. TRPV1 is also sensitive to endocannab-
inoids such as anandamide and N-arachidonoyldopamine,
and 12(S)-hydroperoxyeicosatetraenoic acid (12(S)-HPETE),
which have been also designated as endovanilloids (19).
TRPV1 calcium currents can also be elicited by protons and
by temperatures above 43°C (19).
Activation of TRPV1 has been implicated in several
physiological and pathological conditions, such as body
temperature control, sensitivity to acids in the gastrointes-
tinal mucosa, modulation of vascular tonus, neuropathic
pain, and inflammatory hyperalgesia, among others (19).
The TRPV1 receptor is distributed throughout the whole
body in different tissues, including a large number of areas
in the central nervous system (20).
Early studies with capsaicin showed that this compound
can cause degeneration of primary sensory neurons (21)
and in an appreciable number of areas of the central nervous
system (22). The cell loss elicited by capsaicin has been
related to excess inward calcium currents (23).
One should point out the protective roles of CB1 recep-
tors and some other pro-degenerative roles of TRPV1 in
inflammatory processes in the central nervous system.
However, in addition to the apparent protective role of CB1
receptors, CB1 agonists trigger the release of 12(S)-HPETE
in rat mesencephalic cultures, thus activating calcium in-
flux through TRPV1 receptors and causing neuronal death
due to mitochondrial damage (24). This single example
shows that conclusive statements cannot be made about
the real points of interaction between the two systems.
Additional studies are required to identify the mechanisms
involved in the receptor signaling, metabolic control of
synthesis and degradation of the endocannabinoids/
vanilloids.
Signaling in the nitric oxide system
Nitric oxide (NO) is a freely diffusing gas that can also
be found as a free radical (NO· in its molecular form), which
is involved in diverse physiological processes. In the cen-
tral nervous system, NO is involved in functions that range
from cognition, synaptic plasticity, sleep, neurosecretion,
and appetite to temperature homeostasis (25).
Classically, the synthesis of NO depends upon the
nitric oxide synthase (NOS) enzymes. All cytosolic NOS
isoforms have L-arginine and oxygen as substrates and
NADPH as an electron donor to form NO, thus leading to
the production of NO, citrulline and water (26). Three
cytosolic NOS isoforms have been identified so far. Two of
them are constitutively expressed and are calcium-de-
pendent, and their nomenclature was created based on
the cells in which they are predominating found: the neu-
ronal isoform (nNOS, or type 1, NOS-1), and the endothe-
lial isoform (eNOS, or type 3, NOS-3). The inducible isoform
(iNOS, or type II, NOS-2) is calcium-independent and its
expression was found to be inducible in different tissues.
Indeed, it was found that neurons can also express eNOS
and that iNOS expression can be induced in neuronal
cultures by cytokines. Astrocytes can also express eNOS
and, when activated by inflammatory mediators, may ex-
press iNOS (27).
In addition to the traditional cytoplasmic NO production
sites, NO synthesis has also been reported to occur in
mitochondria (28). Several reports indicate that there is a
specific mitochondrial isoform of NOS, the mitochondrial
NOS. However, recent findings indicate that the release of
NO in the mitochondria of mouse brain, liver and heart is
independent of calcium and of L-arginine and is not abol-
ished in the presence of classical NOS inhibitors, such as
L-NAME and L-NMMA. In addition, NO production in mito-
chondria is dependent on the integrity of this organelle and
on the interaction between complexes I and II and the
ubiquinone complex. There are several possible sources
of NO in the mitochondria, such as NO donors like nitroso-
thiols (29), the conversion of nitrates into NO, and the
conversion of organic nitrates to NO reactive species as
the other possible sources. In addition, it has been shown
that NO can be also produced by nitrate dismutation or
reduction by changes in the pH of the solution (30). The
real existence of mitochondrial NOS is still unclear and this
topic is under intense debate even one decade after its first
description.
After its production, NO can bind to soluble guanylate
cyclase, which in turn converts GMP into cGMP. The
cGMP signaling pathway includes the activation of threo-
nine/serine kinase G (PKG), the activation of sodium and
potassium cyclic nucleotide-gated channels, and the acti-
vation of several phosphodiesterases, which in turn can
modulate PKG action (31).
Nitric oxide in degenerative processes
NO can generate neuronal death in two basic different
ways (32,33). The first mode in which NO was implicated in
neuronal death is by its overproduction. Under these cir-
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cumstances, the presence of reactive oxygen species is
needed for the formation of the more reactive nitrogen
species. The reaction of NO with superoxide (O2·-) can
yield peroxynitrite (ONOO-), which is extremely reactive
and has been implicated in lipid, protein and DNA damage.
Peroxynitrate can apparently form hydroxyl radicals (OH·),
which represent very aggressive oxidant substances, and
nitrite (NO2·), or it can also react with CO2, thus forming
carbonate anion (CO3·-), another oxidant. NO can also
react with oxygen and produce NO2·, which in turn reacts
with other NO molecules to form dinitrogen trioxide (N2O3).
NO2· is able to oxidize or nitrate several molecules. One of
them is tyrosine or tyrosine residues in proteins, generat-
ing 3-nitrotyrosine (32). On the other hand, N2O3 can
nitrosylate (or nitrosate) amines and thiols (S-nitrosylation)
such as glutathione, glyceraldehyde-3 phosphate dehy-
drogenase, and the NR1 and NR2 subunits of the NMDA
receptor, among others (34).
In addition, under acidic conditions such as those
found during hypoxia, peroxynitrate can form peroxyni-
trous acid (ONOOH), which can react in two different ways.
One of them is by forming nitrate (NO3-), which is not a
strong oxidant. The other pathway includes the formation
of nitrogen dioxide (NO2) and possibly OH·, two potent
oxidant molecules that can lead to fatty acid oxidation and
nitration of amino acids (35).
Excessive NO production was also correlated with
neuronal death caused by cessation of mitochondrial res-
piration (33). NO was found to block in a reversible fashion
the mitochondrial cytochrome oxidase, by competing with
oxygen. In addition, NO, nitrosothiols, and peroxynitrate
were implicated in the reversible inactivation of complexes
I and II in mitochondria (36).
These effects of NO on mitochondrial respiration have
been implicated in neuronal death caused by the impair-
ment of sodium-potassium-ATPase, neuronal depolariza-
tion and consequent glutamate excitotoxicity (33). Co-
culture of neuronal cells with LPS/IFN-γ-activated astro-
cytes and microglial cells (which can produce high levels of
NO through iNOS expression) led to neuronal death, which
was prevented by co-incubation with an NMDA receptor
antagonist (37). In other studies, nNOS blocking prevented
cytochrome C impairment in rat cerebellar granule cell
cultures exposed to hypoxia, thus indicating that nNOS
activity could be synergistic with hypoxia, leading to neu-
ronal death. This result agrees with that of another study in
which cortical neurons of nNOS knock-out mice showed
improved resistance to hypoxia and hypoglycemia when
compared to wild-type mice. This was also obtained with
wild-type mice exposed to NMDA blockers (38).
Several studies have shown up-regulation of NO and
nNOS observed in the brain after ischemia or in other
neuropathological conditions such as Alzheimer’s disease
(32). Within the context of lesions and degeneration pro-
cesses related to changes in regulation of nNOS expres-
sion, it is important to mention that several studies have
been conducted using the vertebrate visual system as a
model. However, these studies have reported conflicting
results. For example, some studies have shown that eye
enucleation generated a down-regulation of nNOS in the
superior colliculi and lateral geniculate nuclei of rats (39)
and in the optic tectum of the developing chick (40). In
contrast, an increased expression of NADPH-diaphorase,
a nonspecific NOS marker, was observed after unilateral
optic nerve transection in visual centers of the rat (41).
We have shown that unilateral retinal lesions in 4- to
15-day-old chicks (Gallus gallus) produced a marked in-
crease of nNOS immunoreactivity in the neuropil of the
superficial layers and in perikarya of the deep layers in the
contralateral (deafferented) optic tectum, and increased
expression of the enzyme detected by immunoblotting
(42). Moreover, we observed a higher production of NO in
deafferented tecta using the NO imaging based on the
diaminofluorescein technique. We also observed in this
study that retinal lesions caused a marked decrease in the
number of neuronal nuclei stained for the nuclear protein
Zenk, the product of the early response gene zenk, and in
the immunoreactivity of the 160-kD neurofilament.
Taken together, these results suggest that NOS ex-
pression in visual structures of the chick brain is regulated
negatively by the retinal innervation, which could be an
indication of the participation of NO in plasticity processes
triggered by deafferentation. Despite the conflicting results
reported by different research groups, retinal activity seems
to exert an important influence on the expression of NOS in
visual structures and these differences could reflect dis-
tinct species and developmental stages. It is noteworthy
that the experiments cited above with the chick were
repeated both in the adult rat and the adult mouse with
essentially the same results: up-regulation of nNOS and a
greater production of NO. Furthermore, it was also shown
that the up-regulation was dependent on a transcriptional
mechanism in the visual thalamus, but not in the superior
colliculus, pointing to differential regulation mechanisms
(43).
Nitric oxide and neuroprotection
Notwithstanding its potential harmful effects, NO has
been shown to actually have beneficial effects in neuronal
biology (44). Two pathways that were reported to be acti-
vated by the activation of NO-soluble guanylyl cyclase-
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cGMP and the further activation of PKG are AKT (protein
kinase B) and the transcription factor CREB. It has been
demonstrated that these pathways are involved in neu-
ronal protection mediated by neurotrophic factors.
S-nitrosylation is also another mechanism by which
NO can modulate proteins that could be involved in degen-
erative neuronal processes. It was observed that NO can
nitrosylate the NR1 and NR2 subunits of the NMDA recep-
tor (34), thus blocking excitotoxicity mediated by this re-
ceptor. S-nitrosylation was also suggested as a mechan-
ism by which NO can modulate caspase activation, thus
blocking apoptosis.
NO has also been implicated in the induction of heme
oxygenase 1 in rat microglia, in astrocytes and in the
hippocampus (45). The expression of this protein increases
the biliverdin content of cells, which can be reduced by
biliverdin reductase to bilirubin, a potent antioxidant and
anti-nitrosative compound that has been suggested to
have a role in NO-induced neuroprotection.
Cross-talk between endocannabinoids and
nitric oxide
The relationship between the endocannabinoid and
nitrinergic systems has been extensively reported in cell
biology studies. This includes distinctive interactions at the
level of gene expression and protein function, which are
achieved by direct or indirect interaction between mol-
ecules of the two systems.
It has been reported that endocannabinoids are re-
leased by neurons after brain injury, playing a role in
neuronal protection. This was found in models of traumatic
brain injury, post-NMDA and kainate excitotoxicity, in focal
brain ischemia, and in diabetic retinopathy and macular
degeneration (2,7,12).
One example is that, through alpha-Gi activation, CB1
can modulate calcium inward current and thus modulate
constitutive NOS activation. This is particularly important
in the mediation of NMDA excitotoxicity. CB1 receptor
activation inhibited depolarization of cerebellar granule
cells, thus attenuating cellular calcium influx and blocking
nNOS activity (46). In mouse cerebral cortex, CB1 activa-
tion blocked NO production and reduced cell death (47). In
the same study, the investigators found that nNOS activity
was higher in cortices of CB1 knockout mice than in normal
animals. In the retina, it has been observed that excitotox-
icity elicited by NMDA activation is partially caused by NO-
peroxynitrite formation, which was blocked by co-treat-
ment with delta-9-tetrahydroxycannabinol (48).
In contrast, there is evidence that the direct signaling
elicited by CB1 activation can lead to NO production. CB1
activation seemed to lead to NO production in several
neuronal culture lines and in brain slices (49). Hence,
TRPV1 activation in cat dorsal neck muscles increased
NADPH-diaphorase activity in the cervical and lumbar
spine, thus indicating that activation of peripheral TRPV1
receptors is involved in central plasticity (50). Recently, it
was also reported that CB1 activation in N18TG2 neuro-
blastoma cells resulted in translocation of the ß1 subunit of
soluble guanylyl cyclase to the membrane (51). The inves-
tigators speculated that the translocation of soluble guany-
lyl cyclase to the membrane may be a permissive factor,
which provides a higher efficiency in signals triggered by
NO stimulation of this enzyme.
NO has also been implicated in the facilitation of
anandamide binding to the TRPV1 receptor. Interestingly,
the binding of anandamide to TRPV1 receptor occurs in
the intracellular domain of this receptor, and it has been
shown that the action of anandamide on the TRPV1 recep-
tor depends on self-production by the cells or by rapid
transport of extracellular anandamide to the intracellular
space (19). This has been attributed to both diffusion
through the cellular membrane and to AMT. AMT activity
was shown to be affected by several agents, including NO,
which can enhance the transport of anandamide through
membranes, permitting anandamide access to the intra-
cellular space, where it can activate the TRPV1 receptor
(19).
Cannabinoids have been shown to modulate microglia
function. Rat cortical microglial cells express CB1 recep-
tors, and their activation leads to inhibition of NO produc-
tion (52). It was shown that mouse microglial cells produce
higher concentrations of 2-AG when activated by high ATP
concentrations. 2-AG and other cannabinoids, through
activation of CB2 receptors and abnormal-cannabidiol-
sensitive receptors and subsequent activation of ERK 1/2,
also increased microglial cell migration (53). Conversely, it
was found that S-nitrothiols such as S-nitrosoglutathione
and S-nitrosocysteine can reversible block CB1 receptor
activation of a Gi-protein (54). S-nitrosothiols, as discussed
previously, can transnitrosilate several proteins at their
thiol residues in a reversible manner, thus modulating the
function of diverse proteins.
It has been recently reported that activation of the CB1
receptor by ACEA, a CB1 agonist, and other agonists
prevented iNOS expression and cell death in rat forebrain
cultures deprived of oxygen and glucose, a model that
mimics focal ischemia (55). Despite the direct effects of
endocannabinoids on CB1 and CB2 receptors, it has been
shown that activation of TRPV1 in isolated mouse retinal
microglial cells can induce nuclear factor kappa ß translo-
cation (56), which is known to activate iNOS transcription.
73
Braz J Med Biol Res 42(1) 2009
Neurotransmission, neurodegeneration, neuroprotection
www.bjournal.com.br
We have been performing several experiments in order
to study the relationship between the nitrinergic and the
vanilloid systems in the rat retina (Leonelli M, Martins DO,
Britto LRG, unpublished data). Double-labeling immuno-
fluorescence experiments were used to determine whether
the TRPV1 receptor is expressed in retinal microglial cells.
We found that TRPV1 immunoreactivity was present in
OX-42-positive microglial cells, with a preferential localiza-
tion in cellular processes. We then performed LPS in-
traocular injections (5 μL, 1 μM), which are known to
induce iNOS expression. In such cells, we found minor
TRPV1 labeling. We also tested whether capsaicin, a
TRPV1 agonist, could induce iNOS expression. Intravitreal
injections of capsaicin were induced by iNOS expression
in these cells, albeit lesser in intensity. In the same model,
we performed immunoblotting and immunoperoxidase as-
says to determine whether capsaicin treatment affected
protein nitration. We found a higher 3-nitrotyrosine signal
in both experiments, which was completely blocked by the
concomitant capsazepine treatment. Recently, it was re-
ported that capsaicin lead to iNOS expression in PC12
cells (57). However, this was not blocked by capsazepine,
the TRPV1 receptor antagonist. It was also shown that
capsaicin also generates superoxide in C6 glioma cells,
thus enhancing nitrosative stress and protein nitrosylation
(58). Hence, our experiments indicated that retinal micro-
glial cells expresses the TRPV1 receptor and that its direct
activation could lead to nitrosative stress, which was blocked
by capsazepine.
Recently, it was demonstrated that TRPV1 activation
previous to a high pressure-induced ischemic lesion in the
rat retina reduced the loss of retinal ganglion cells (59). In
the same study, these investigators indicated that the high
pressure-induced ischemic lesion triggered fatty acid amide
hydrolase to a higher expression level, thus lowering
anandamide concentrations in the retina. Our results indi-
cate that TRPV1 expression can also be detected in retinal
blood vessels. Endocannabinoids seem to modulate vas-
cular tonus by acting both on CB1 and TRPV1 receptors. In
fact, NO was also released by TRPV1 stimulation in endo-
thelial cells from rat mesenteric bed (60).
On the basis of these considerations, we hypothesize
that TRPV1 protection in the ischemic model could be due
to a previous activation of TRPV1 receptor (59) and possi-
bly to eNOS activation and vasodilatation, thus preventing
ischemia-induced neuronal damage.
Concluding remarks
The data presented in this review indicate that the
cannabinoid, vanilloid and nitrinergic systems are all in-
volved in several aspects of the neural functions, in addi-
tion to conventional neurotransmission. More knowledge
of the mechanisms involved in their regulation after brain
injury, and of their interactions, is necessary to enable the
neurosciences to fulfill their ultimate task, which is the
generation of therapeutical tools to minimize neurodegen-
eration.
Acknowledgments
Thanks are due to Maria Fernanda R. Graciano (USP)
and Eduardo R.L. de Oliveira (University of São Paulo) for
critically reading the manuscript.
References
1. Di Marzo V, Deutsch DG. Biochemistry of the endogenous
ligands of cannabinoid receptors. Neurobiol Dis 1998; 5:
386-404.
2. Fride E. Endocannabinoids in the central nervous system -
an overview. Prostaglandins Leukot Essent Fatty Acids
2002; 66: 221-233.
3. Piomelli D. The molecular logic of endocannabinoid signal-
ling. Nat Rev Neurosci 2003; 4: 873-884.
4. Piomelli D, Greengard P. Lipoxygenase metabolites of ara-
chidonic acid in neuronal transmembrane signalling. Trends
Pharmacol Sci 1990; 11: 367-373.
5. Stella N, Piomelli D. Receptor-dependent formation of en-
dogenous cannabinoids in cortical neurons. Eur J Pharma-
col 2001; 425: 189-196.
6. Ohno-Shosaku T, Hashimotodani Y, Maejima T, Kano M.
Calcium signaling and synaptic modulation: regulation of
endocannabinoid-mediated synaptic modulation by cal-
cium. Cell Calcium 2005; 38: 369-374.
7. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA,
Hampson RE, Porrino LJ. Cannabinoid physiology and phar-
macology: 30 years of progress. Neuropharmacology 2004;
47 (Suppl 1): 345-358.
8. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner
TI. Structure of a cannabinoid receptor and functional ex-
pression of the cloned cDNA. Nature 1990; 346: 561-564.
9. Munro S, Thomas KL, Abu-Shaar M. Molecular character-
ization of a peripheral receptor for cannabinoids. Nature
1993; 365: 61-65.
10. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi
PA, et al. Discovery of the presence and functional expres-
sion of cannabinoid CB2 receptors in brain. Ann N Y Acad
Sci 2006; 1074: 514-536.
11. He JC, Neves SR, Jordan JD, Iyengar R. Role of the Go/i
signaling network in the regulation of neurite outgrowth. Can
74
Braz J Med Biol Res 42(1) 2009
M. Leonelli et al.
www.bjournal.com.br
J Physiol Pharmacol 2006; 84: 687-694.
12. Grundy RI, Rabuffetti M, Beltramo M. Cannabinoids and
neuroprotection. Mol Neurobiol 2001; 24: 29-51.
13. Glass M, Dragunow M, Faull RL. The pattern of neurode-
generation in Huntington’s disease: a comparative study of
cannabinoid, dopamine, adenosine and GABA(A) receptor
alterations in the human basal ganglia in Huntington’s dis-
ease. Neuroscience 2000; 97: 505-519.
14. Chaves GP, Nogueira TC, Britto LR, Bordin S, Torrao AS.
Retinal removal up-regulates cannabinoid CB(1) receptors
in the chick optic tectum. J Neurosci Res 2008; 86: 1626-
1634.
15. Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I,
Berrendero F, Manzanares J, et al. Anandamide, but not 2-
arachidonoylglycerol, accumulates during in vivo neurode-
generation. J Neurochem 2001; 78: 1415-1427.
16. Romero J, Berrendero F, Perez-Rosado A, Manzanares J,
Rojo A, Fernandez-Ruiz JJ, et al. Unilateral 6-hydroxydop-
amine lesions of nigrostriatal dopaminergic neurons in-
creased CB1 receptor mRNA levels in the caudate-puta-
men. Life Sci 2000; 66: 485-494.
17. Pedersen SF, Owsianik G, Nilius B. TRP channels: an
overview. Cell Calcium 2005; 38: 233-252.
18. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA,
Levine JD, Julius D. The capsaicin receptor: a heat-acti-
vated ion channel in the pain pathway. Nature 1997; 389:
816-824.
19. Di Marzo V, Blumberg PM, Szallasi A. Endovanilloid signal-
ing in pain. Curr Opin Neurobiol 2002; 12: 372-379.
20. Starowicz K, Nigam S, Di Marzo V. Biochemistry and phar-
macology of endovanilloids. Pharmacol Ther 2007; 114: 13-
33.
21. Jancso G, Kiraly E, Jancso-Gabor A. Pharmacologically
induced selective degeneration of chemosensitive primary
sensory neurones. Nature 1977; 270: 741-743.
22. Ritter S, Dinh TT. Capsaicin-induced neuronal degeneration
in the brain and retina of preweanling rats. J Comp Neurol
1990; 296: 447-461.
23. Grant ER, Dubin AE, Zhang SP, Zivin RA, Zhong Z. Simul-
taneous intracellular calcium and sodium flux imaging in
human vanilloid receptor 1 (VR1)-transfected human em-
bryonic kidney cells: a method to resolve ionic dependence
of VR1-mediated cell death. J Pharmacol Exp Ther 2002;
300: 9-17.
24. Kim SR, Bok E, Chung YC, Chung ES, Jin BK. Interactions
between CB(1) receptors and TRPV1 channels mediated
by 12-HPETE are cytotoxic to mesencephalic dopaminergic
neurons. Br J Pharmacol 2008; 155: 253-264.
25. Guix FX, Uribesalgo I, Coma M, Munoz FJ. The physiology
and pathophysiology of nitric oxide in the brain. Prog Neuro-
biol 2005; 76: 126-152.
26. Bredt DS, Snyder SH. Nitric oxide, a novel neuronal mes-
senger. Neuron 1992; 8: 3-11.
27. Alderton WK, Cooper CE, Knowles RG. Nitric oxide syn-
thases: structure, function and inhibition. Biochem J 2001;
357: 593-615.
28. Ghafourifar P, Richter C. Nitric oxide synthase activity in
mitochondria. FEBS Lett 1997; 418: 291-296.
29. Steffen M, Sarkela TM, Gybina AA, Steele TW, Trasseth
NJ, Kuehl D, et al. Metabolism of S-nitrosoglutathione in
intact mitochondria. Biochem J 2001; 356: 395-402.
30. Zweier JL, Samouilov A, Kuppusamy P. Non-enzymatic
nitric oxide synthesis in biological systems. Biochim Biophys
Acta 1999; 1411: 250-262.
31. Esplugues JV. NO as a signalling molecule in the nervous
system. Br J Pharmacol 2002; 135: 1079-1095.
32. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxy-
nitrite in health and disease. Physiol Rev 2007; 87: 315-424.
33. Brown GC, Bal-Price A. Inflammatory neurodegeneration
mediated by nitric oxide, glutamate, and mitochondria. Mol
Neurobiol 2003; 27: 325-355.
34. Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P,
Snyder SH. Protein S-nitrosylation: a physiological signal
for neuronal nitric oxide. Nat Cell Biol 2001; 3: 193-197.
35. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman
BA. Apparent hydroxyl radical production by peroxynitrite:
implications for endothelial injury from nitric oxide and su-
peroxide. Proc Natl Acad Sci U S A 1990; 87: 1620-1624.
36. Brown GC, Borutaite V. Inhibition of mitochondrial respira-
tory complex I by nitric oxide, peroxynitrite and S-nitrosothi-
ols. Biochim Biophys Acta 2004; 1658: 44-49.
37. Bal-Price A, Brown GC. Inflammatory neurodegeneration
mediated by nitric oxide from activated glia-inhibiting neu-
ronal respiration, causing glutamate release and excitotox-
icity. J Neurosci 2001; 21: 6480-6491.
38. Dawson VL, Kizushi VM, Huang PL, Snyder SH, Dawson
TM. Resistance to neurotoxicity in cortical cultures from
neuronal nitric oxide synthase-deficient mice. J Neurosci
1996; 16: 2479-2487.
39. Zhang C, Granstrom L, Wong-Riley MT. Deafferentation
leads to a down-regulation of nitric oxide synthase in the rat
visual system. Neurosci Lett 1996; 211: 61-64.
40. Williams CV, Nordquist D, McLoon SC. Correlation of nitric
oxide synthase expression with changing patterns of axonal
projections in the developing visual system. J Neurosci
1994; 14: 1746-1755.
41. Yan XX, Garey LJ, Liang Y, von Bussmann KA, Jen LS.
Increased expression of NADPH-diaphorase in visual cen-
tres after unilateral optic nerve transection in the rat. J
Hirnforsch 1995; 36: 485-488.
42. Torrao AS, Britto LR. Increased expression of nitric oxide
synthase in visual structures of the chick brain after retinal
removal. J Neurosci Res 2004; 78: 123-131.
43. Chacur M, Matos RJ, Batista SS, Kihara AH, Britto LR.
Differential regulation of the neuronal isoform of nitric oxide
synthase in the superior colliculus and dorsal lateral genicu-
late nucleus of the adult rat brain following eye enucleation.
Int J Dev Neurosci 2006; 24: 461-468.
44. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield
DA, Stella AM. Nitric oxide in the central nervous system:
neuroprotection versus neurotoxicity. Nat Rev Neurosci
2007; 8: 766-775.
45. Kitamura Y, Furukawa M, Matsuoka Y, Tooyama I, Kimura
H, Nomura Y, et al. In vitro and in vivo induction of heme
oxygenase-1 in rat glial cells: possible involvement of nitric
oxide production from inducible nitric oxide synthase. Glia
1998; 22: 138-148.
46. Hillard CJ, Muthian S, Kearn CS. Effects of CB(1) cannabi-
noid receptor activation on cerebellar granule cell nitric ox-
ide synthase activity. FEBS Lett 1999; 459: 277-281.
47. Kim SH, Won SJ, Mao XO, Jin K, Greenberg DA. Molecular
mechanisms of cannabinoid protection from neuronal exci-
75
Braz J Med Biol Res 42(1) 2009
Neurotransmission, neurodegeneration, neuroprotection
www.bjournal.com.br
totoxicity. Mol Pharmacol 2006; 69: 691-696.
48. El-Remessy AB, Khalil IE, Matragoon S, Abou-Mohamed G,
Tsai NJ, Roon P, et al. Neuroprotective effect of (-)Delta9-
tetrahydrocannabinol and cannabidiol in N-methyl-D-aspar-
tate-induced retinal neurotoxicity: involvement of peroxyni-
trite. Am J Pathol 2003; 163: 1997-2008.
49. Mukhopadhyay S, Shim JY, Assi AA, Norford D, Howlett
AC. CB(1) cannabinoid receptor-G protein association: a
possible mechanism for differential signaling. Chem Phys
Lipids 2002; 121: 91-109.
50. Pilyavskii AI, Maznychenko AV, Maisky VA, Kostyukov AI,
Hellstrom F, Windhorst U. Capsaicin-induced effects on c-
fos expression and NADPH-diaphorase activity in the feline
spinal cord. Eur J Pharmacol 2005; 521: 70-78.
51. Jones JD, Carney ST, Vrana KE, Norford DC, Howlett AC.
Cannabinoid receptor-mediated translocation of NO-sensi-
tive guanylyl cyclase and production of cyclic GMP in neu-
ronal cells. Neuropharmacology 2008; 54: 23-30.
52. Waksman Y, Olson JM, Carlisle SJ, Cabral GA. The central
cannabinoid receptor (CB1) mediates inhibition of nitric ox-
ide production by rat microglial cells. J Pharmacol Exp Ther
1999; 288: 1357-1366.
53. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, et
al. Nonpsychotropic cannabinoid receptors regulate micro-
glial cell migration. J Neurosci 2003; 23: 1398-1405.
54. Kokkola T, Savinainen JR, Monkkonen KS, Retamal MD,
Laitinen JT. S-nitrosothiols modulate G protein-coupled re-
ceptor signaling in a reversible and highly receptor-specific
manner. BMC Cell Biol 2005; 6: 21.
55. Fernandez-Lopez D, Martinez-Orgado J, Nunez E, Romero
J, Lorenzo P, Moro MA, et al. Characterization of the neuro-
protective effect of the cannabinoid agonist WIN-55212 in
an in vitro model of hypoxic-ischemic brain damage in new-
born rats. Pediatr Res 2006; 60: 169-173.
56. Sappington RM, Calkins DJ. Contribution of TRPV1 to mi-
croglia-derived IL-6 and NFkappaB translocation with el-
evated hydrostatic pressure. Invest Ophthalmol Vis Sci
2008; 49: 3004-3017.
57. Qiao S, Li W, Tsubouchi R, Murakami K, Yoshino M. Role of
vanilloid receptors in the capsaicin-mediated induction of
iNOS in PC12 cells. Neurochem Res 2004; 29: 687-693.
58. Qiao S, Li W, Tsubouchi R, Haneda M, Murakami K, Yoshino
M. Involvement of peroxynitrite in capsaicin-induced apop-
tosis of C6 glioma cells. Neurosci Res 2005; 51: 175-183.
59. Nucci C, Gasperi V, Tartaglione R, Cerulli A, Terrinoni A,
Bari M, et al. Involvement of the endocannabinoid system in
retinal damage after high intraocular pressure-induced is-
chemia in rats. Invest Ophthalmol Vis Sci 2007; 48: 2997-
3004.
60. Poblete IM, Orliac ML, Briones R, Adler-Graschinsky E,
Huidobro-Toro JP. Anandamide elicits an acute release of
nitric oxide through endothelial TRPV1 receptor activation
in the rat arterial mesenteric bed. J Physiol 2005; 568: 539-
551.
